Tianyin to Present at the BMC 2010 Life Sciences Summit at New York on May 17

CHENGDU, China, May 17 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a biopharmaceutical company that specializes in modernized traditional Chinese medicine ("TCM") and branded generics is invited to present at the Brean Murray Carret & Co. 2010 Life Sciences Summit in New York, NY.

    Presentation time: 2:00pm-3:00pm ET, The Grand Hyatt Hotel, Ballroom I
    Panel discussion:  Winners and losers of China healthcare reform:
                       Game not over-what's done and what to expect.
    Presenter:         Dr. James Jiayuan Tong, CFO, CBDO, Director of Tianyin
                       Pharmaceutical

About Tianyin Pharmaceuticals

Tianyin Pharmaceutical Co., Inc., headquartered in Chengdu, Sichuan Province of China, is a leading biopharmaceutical company that is engaged in the development, manufacturing, marketing and sale of modernized traditional Chinese medicines and branded generics, equipped with two state-of-the-art manufacturing facilities and an extensive nationwide sales and distribution network throughout China. Tianyin currently manufactures and markets a comprehensive portfolio of 52 products, of which 23 are listed in the highly selective National Medicine Catalog of the National Medical Insurance program, 7 are included in the essential drug list of China. Tianyin achieved 10 new drug approvals at SFDA in 2009 and has a pipeline of 12 products pending regulatory approval that target various indications with considerable market potential. Tianyin has an extensive nationwide distribution network with a sales force of 720 sales representatives out of totaled 1,365 employees. For more information about Tianyin, please visit http://www.tianyinpharma.com .

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

    For more information, please contact:

     James Jiayuan Tong M.D. Ph.D.
     Chief Financial Officer, Chief Business & Development Officer
     Director
     Tianyin Pharmaceutical Co., Inc.
     Web:     http://www.tianyinpharma.com
     Email:   [email protected]
     Tel:     +86-28-8551-6696 (Chengdu, China)
              +1-949-350-6999 (U.S.)
              +86-134-3655-0011 (China)
     Address: 23rd Floor Unionsun YangKuo Plaza
              No 2 Block 3 South Renmin Road
              Chengdu, 610041
              China

SOURCE Tianyin Pharmaceutical Co., Inc.